Two Sigma Advisers
THRX

Two Sigma Advisers’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Two Sigma Advisers’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,900
Closed -$72.5K – 2701
2023
Q4 		$72.5K Buy
17,900
+5,700
+47% +$17.4K ﹤0.01% 2363
2023
Q3 		$32.8K Sell
12,200
-18,000
-60% -$70.5K ﹤0.01% 2301
2023
Q2 		$282K Buy
30,200
+1,800
+6% +$17.7K ﹤0.01% 1995
2023
Q1 		$252K Buy
+28,400
New +$279K ﹤0.01% 2201

Two Sigma Advisers's THRX Position: Q1 2024 in Review

Two Sigma Advisers sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 17,900 shares — an estimated $72.5K sold.

Two Sigma Advisers first reported a position in THRX in Q1 2023 and held it in 4 quarters. The position peaked at $282K in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

  • Two Sigma Advisers reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 17,900 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $72.5K.
  • Two Sigma Advisers first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 4 quarters.
  • Two Sigma Advisers's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $282K in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Two Sigma Advisers's 13F filing for Q1 2024, filed 15 May 2024.